

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/076,514	02/19/2002	Ludwig Volkel	52203	3431
7590 02/09/2004 · Herbert B. Keil			EXAMINER	
			YOUNG, MICAH PAUL	
KEIL & WEINKAUF 1101 Connecticut Ave., N.W.		ART UNIT	PAPER NUMBER	
Washington, DC 20036			1615	
			DATE MAILED: 02/09/2004	4

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
	10/076,514	VOLKEL ET AL.				
Office Action Summary	Examin r	Art Unit				
•	Micah-Paul Young	1615				
The MAILING DATE of this communication app						
Peri d for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period was reply reply to the period of the period for reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	i6(a). In no event, however, may a reply be tim within the statutory minimum of thirty (30) days ill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status						
1)⊠ Responsive to communication(s) filed on 24 No.	ovember 2003.					
3) Since this application is in condition for allowar						
,	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims						
4) Claim(s) <u>1-11</u> is/are pending in the application.						
· · · · · · · · · · · · · · · · · · ·	4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.						
6) Claim(s) 1-11 is/are rejected.	. /					
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	Claim(s) are subject to restriction and/or election requirement.					
Application Papers						
9) The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)).	on No ed in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)	4) Interview Summary					
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) 	Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	ate atent Application (PTO-152)				
Paper No(s)/Mail Date						

Art Unit: 1615

DETAILED ACTION

Acknowledgement of Papers Received: Amendment/Response filed

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 1. Claims 1, 10 and 11 are rejected under 35 U.S.C. 102(b) as being anticipated by Spires (USPN 4,394,377 hereafter referred to as '377). The claim is drawn to a choline abscorbate in form of crystals.

'377 discloses crystalline choline salts made with organic and inorganic acids.

According to '377, the crystalline salts including choline abscorbate are available commercially (col. 3, lin. 62 – col. 4, lin. 7). The crystals can be incorporated into ruminant animal supplement (col. 4, lin. 28 – 35) These disclosures render the claims anticipated.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Art Unit: 1615

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

2. Claims 3-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Spires (USPN 4,394,377 hereafter referred to as '377) and Klein et al (USPN 2,870,198 hereafter referred to as '198). The claims are drawn to a choline abscorbate crystal and a process for making.

As discussed above '377 discloses a crystalline choline abscorbate. '377 also discloses other crystalline salts of choline including choline citrate and bitartrate, however does not disclose the process by which the crystals are formed. Crystallization is a common form of isolation well known in the art. Isolation with ethylene oxide and trimethylamine, at low temperature is well known in the art as seen in '759 (col. 2, lin. 18 – 59). Organic acids such as anhydrous citric acid are used in the reaction (examples). It would be within the level of skill in the art to produce the choline abscorbate of '377 by the process of '198 by substituting ascorbic acid as the organic acid.

With regard to claims 3 – 5 which recite the diffraction characteristics of the compound, it is the position of the examiner that these characteristics would be inherent to the compound recited in the art. Presented here is a crystalline choline abscorbate free from water of crystallization, and processed from reacting ascorbic acid, trimethylamine and ethylene oxide, at a temperature below 40°C. Barring a showing of unexpected results or evidence to the contrary it is the position of the examiner that the compounds of the present invention and the compound recited by the art are identical, hence having identical properties including diffraction

Art Unit: 1615

characteristics. The diffraction information claimed can be determined through routine experimentation by artisans of ordinary skill and do not impart patentability on the formulation.

Also the Office does not have the facilities for examining and comparing applicant's product with the product of the prior art in order to establish that the product of the prior art does not possess the same material structural and functional characteristics of the claimed product. In the absence of evidence to the contrary, the burden is upon the applicant to prove that the claimed products are functionally different than those taught by the prior art and to establish patentable differences. *See Ex parte Phillips*, 28 U.S.P.Q.2d 1302, 1303 (PTO Bd. Pat. App. & Int. 1993), *Ex parte Gray*, 10 USPQ2d 1922, 1923 (PTO Bd. Pat. App. & Int.) and *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977).

With these things in mind a skilled artisan would have been motivated to process the crystalline choline abscorbate by the process of '198 with a simple substitution of the organic acid. As seen by '377 the crystals are useful as dietary supplements for ruminant animals. A skilled artisan would have been motivated make the crystals in this way in order to yield a crystal of higher purity. '337 establishes a relationship between choline citrate and abscorbate salts. '198 teaches a method of making choline citrate salt crystals. A skilled artisan would be able to substitute abscorbate into the preparation. It would have been obvious to a skilled artisan to combine these teachings and suggestions with an expected result of a substantially pure crystalline choline abscorbate with pharmaceutical applications.

Correspondence

Art Unit: 1615

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Micah-Paul Young whose telephone number is 571-272-0608.

The examiner can normally be reached on M-F 7:00-4:30 every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Thurman K Page can be reached on 571-272-0602. The fax phone number for the

organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Micah-Paul Young

Examiner

Art Unit 1615

MP Young

Gollamudi S. Kishore, PhD

Primary Examiner

Group 1/500